| Line Item | 2026-01-02 | Y/Y |
|---|---|---|
| Revenue | $17.17B | +3.1% |
| Cost of Revenue | $14.07B | +1.5% |
| R&D Expense | $187.0M | +24.7% |
| SG&A Expense | $999.0M | +1.6% |
| Operating Income | $2.11B | +15.4% |
| Pre-tax Income | $1.91B | +16.5% |
| Income Tax | $447.0M | +15.2% |
| Net Income | $1.45B | +15.5% |
| EPS (Basic) | $11.31 |
| Line Item | 2026-01-02 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.11B | +17.5% |
| Accounts Receivable | $2.71B | +2.4% |
| Inventory | $342.0M | +8.6% |
| Current Assets | $4.81B | +8.7% |
| Total Assets | $13.49B | +3.0% |
| Current Liabilities | $2.83B | -22.6% |
| Long-term Debt | $4.63B | +14.2% |
| Line Item | 2026-01-02 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.75B | +25.7% |
| Investing Cash Flow | -$405.0M | -185.2% |
| Financing Cash Flow | -$1.15B | -5.6% |
| +20.8% |
| EPS (Diluted) | $11.14 | +20.8% |
| Total Liabilities |
| $8.53B |
| -1.3% |
| Stockholders' Equity | $4.92B | +11.4% |